VLValeriya Aleksandrovna Lemeshko

Valeriya Aleksandrovna Lemeshko

*This is an algorithmically generated author record based on publicly available information.

Valeriya Aleksandrovna Lemeshko has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quality assessment of inpatient antimicrobial therapy using a multi-criteria decision analysis model

    by Varyukhina, V.A. Lemeshko, S.S. Otstavnov

    Objective. To develop an integral antimicrobial therapy quality index (AMTQI) using the multi-criteria decision analysis (MCDA) methodology and to validate the calculation models in an in-hospital setting. Materials and methods. Based on the content analysis and expert questionnaires, a set of criteria for assessing the quality of antimicrobial therapy (AMT), assessment scales were developed, and weight coefficients (WC) were calculated using the direct weighting (DW) method and the indirect method of Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA). Based on the obtained WCs, a simple linear aggregation model (SLAM) with two sets of WCs (DW and PAPRIKA) and a multi-attribute value theory (MAVT) with a set of PAPRIKA WCs were created. Model validation and scenario sensitivity analysis were performed on 10 case histories of patients in an inpatient department. Results. A list of 12 AMT quality criteria was created; the WC criteria using DW were comparable, while the PAPRIKA method showed more differences between the WCs. When calculating AMTQI, the comparability of the assessment for each AMT case was found (mean SLAM (DW) value was 73.3±26.2, SLAM (PAPRIKA) 73.0±24.9, and MAVT (PAPRIKA) 72.1±25.1 points). The result rankings were the same in the SLAM models and differed in the two patients in the MAVT. All models demonstrated robustness for 8 of the 12 criteria in the scenario sensitivity analysis. Conclusion. A MCDA method can be used to develop a model of an AMTQI based on a comprehensive set of universal criteria, with the SLAM and MAVT models appearing comparable. However, the results obtained need to be confirmed using more data. The AMTQI can be used in the internal and external audit of quality control of medical care in healthcare organizations.

  • Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis by means of sublingual allergen-specific immunotherapy

    by Valeriya A. Lemeshko, Svetlana S. Ratushnyak, Filipp V. Gorkavenko, Evgeniya V. Nazarova, Natalia I. Ilina, Vitaly V. Omelyanovskiy, Омельяновский Виталий Владимирович

    BACKGROUND: Allergic rhinitis is the most common chronic allergic disease worldwide, and bronchial asthma (BA) is one of the most severe complications of allergic rhinitis. Clinical studies reported that sublingual allergen-specific immunotherapy can reduce the incidence of bronchial asthma in children and adults. However, allergen-specific immunotherapy is rather expensive and is not reimbursed by the state, which transfers the cost of this therapy to patients. AIMS: To evaluate the cost-effectiveness of allergen-specific immunotherapy in children and adults with allergic rhinitis and/or allergic rhinoconjunctivitis MATERIALS AND METHODS: The study hypothesized based on study results by Devillier P. et al. in 2019, to which the incidence of asthma was 13.7% and 17.0% in the sublingual allergen-specific immunotherapy + symptomatic therapy and the symptomatic therapy group, respectively (odds ratio: 0.776, 95% confidence interval [0.622; 0.968]). Pharmacoeconomic study based on decision tree model. Costs taken into account are the following: allergen-specific immunotherapy, symptomatic therapy, diagnostics, and routine follow-up visits due to bronchial asthma, outpatient bronchial asthma drug therapy, and hospitalization due to bronchial asthma. The modeling horizon was 5 years, including 2 years of allergen-specific immunotherapy therapy and 3 years of follow-up. RESULTS: The cost per patient when using allergen-specific immunotherapy in combination with symptomatic therapy was 166,711.93 rubles, whereas with symptomatic therapy was 101,700.35 rubles. The cost-effectiveness ratio for allergen-specific immunotherapy in combination with symptomatic therapy was 193,177.20 rubles per 1 prevented case of asthma, whereas 122,530.55 rubles for symptomatic therapy for 1 prevented case of bronchial asthma. Thus, the cost of 1 averted bronchial asthma case when using allergen-specific immunotherapy in combination with symptomatic therapy is 57.7% higher than with symptomatic therapy. The cost-benefit analysis result revealed that the incremental cost-utility ratio for an additional year of life adjusted for its quality when performing sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared with symptomatic therapy alone in children and adults was 567,365.48 rubles, which is less than the calculated willingness to pay threshold (RUB 2,248,898.50). CONCLUSIONS: The comparison results of the cost of 1 added quality adjusted life years and willingness to pay threshold concluded that sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared to symptomatic therapy alone is potentially cost-effective in children and adults with allergic rhinitis.


  • Open Access

    Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy

    by V. A. Lemeshko, K. I. Matrenin, V. V. Omelyanovskiy, Yu. V. Vasilyeva, G. R. Khachatryan, L. A. Kolganov

    Objective: the development and approbation of the method for comparative analysis of the lists of medicines in different countries and systems of healthcare.Material and methods. Based on the open-access data on the lists of medicines published on official websites of the authorized regulators, the authors selected the national lists of medicines of Russia, England, and Italy for the development and approbation of the method. It was proposed to use three parameters: the absolute number of medicines by international nonproprietary name (INN); the structure of the lists based on anatomical therapeutic chemical (ATC) classification; and the coverage of the indications based on the International Classification of Diseases, 10th edition (ICD-10). The results of the analysis provided grounds for the review of the approaches to the formation of the lists of medicines required for medical help in Russia, England, and Italy and reimbursed from the state budget.Results. The number of medicines by INN in the national lists of England and Italy exceeds the total number of drugs included in the list of vital essential and desirable (VED) in Russia. All the analyzed lists were characterized by an uneven distribution of medicines within the lists by the ATC groups. The lists of medicines in England and Italy significantly exceed the list of VED by the number of the included medicines by all ATC groups excluding groups J and H in comparison with Italy, and groups J and V in comparison with England. At the same time, the list of VED significantly exceeds the list in England by the number of covered indications from the ATC L group. During the approbation, the method showed to be effective and can be used for further comparative studies of the national lists of medicines.Conclusion. Non-uniform lists of medicines by ATC-codes show that each country has priority areas in their healthcare systems. The list of VED can be shorter by the absolute number of the included medicines in England and Italy but it can exceed them by the coverage of indications due to peculiarities of the procedure of the list formation (reimbursement of medicines by all the registered indications). The results of the study with the proposed method can serve for the optimization of the VED list and the analysis of therapeutic areas that are undercovered.


  • Open Access

    Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making

    by V. A. Lemeshko, N. Z. Musina, V. V. Omelyanovskiy

    Aim. Development of a tool for the evaluation of the therapeutic value of anticancer drugs based on multi-criteria analysis of decision making.Materials and methods. The study included 4 main stages. At the first stage, based on the results of the publications analysis and the EVIDEM system, a list of therapeutic value criteria was formed. At the second stage, for each criterion, a survey of experts was used to develop a scale and to build a value function using the curve-fitting method. At the third stage, the weighing was carried out using the discrete choice experiment method and the statistical package "support.CEs" in R Studio. At the fourth stage, based on the obtained values of the weight coefficients and value functions, a simple linear additive model was constructed.Results. The authors developed a tool that included 5 criteria for the value of anticancer drugs: efficacy, safety, disease severity, ease of administration, and therapeutic need. For each criterion, a linear value function was built, which allowed the authors to obtain the value of the severity of the criterion in the range from 0 to 1 based on the absolute values of the criterion for a particular drug. As a result of the weighing, two sets of weighting coefficients were obtained by using two different methods of survey results processing. The criterion of efficacy has the most significant contribution to the therapeutic value for the Russian health care system, and the least significant is the severity of the disease. The distribution of the criteria in the intermediate contribution ranks was significantly different between the two sets of weights.Conclusions. For practical application and implementation of the proposed tool, it is required to conduct the validation using the example of specific antitumor drugs to select a final set of weighting coefficients, check the stability of the results, and form a scale of therapeutic value levels.


  • Open Access

    Affordability of in vivo gene therapy. Problems and potential solutions

    by V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko

    Affordability of in vivo gene therapy. Problems and potential solutions

  • Open Access

    Drug provision and health technology assessment in France

    by V. V. Omelyanovskiy, A. V. Nikitina, V. A. Lemeshko, G. R. Khachatryan

    The article presents the description of structural, organizational and methodological issues of health technology assessment (HTA) of French drugs as well as the state-reimbursable list of drugs. The HTA is conducted by an independent public body – French National Authority for Health (HAS). HAS evaluates medical products, procedures, services and technologies from a medical and economic points of view to make cost recovery decisions. HAS consists of two committees providing HTA: Transparency Committee and the Economic and Public Health Assessment Committee. Thus, the French HTA consists of two separate components within the same agency. The result of HAS evaluation of a drug is a conclusion on the level of clinical value and clinical added value, as well as the methodological quality of the studies and the size of the target patient population. Based on the evaluation results, HAS gives recommendations for the National Union of Health Insurance Funds, the Economic Committee for Healthcare Products and Ministry of Health and publishes its opinion on the HAS website. HAS decisions are of a recommendatory nature – the final decision whether to include the drug in reimbursement lists are made by the Ministry of Health and published in the Official Journal of French republic.

  • THE CONCEPT OF VALUE-BASED HEALTHCARE: OPPORTUNITIES FOR DRUG PRICING

    by Valeriya Aleksandrovna Lemeshko, Nuriya Zagitovna Musina

    Представлен обзор методологических подходов к проведению ценностно-ориентированного ценообразования (value-basedpricing), в рамках которого были рассмотрены принципы определение ценности лекарственных препаратов и преобразования полученного значения ценности в цену. В рамках этапа определения ценности выделены два основных подхода: использование в качестве критерия ценности показателя количества лет жизни с учетом ее качества (quality-adjusted life-year, QALY) и применение многокритериального определения ценности. На основании этого в дальнейшем определяется подход к расчету непосредственно цены на лекарственный препарат. Классическим является использование анализа «затраты-эффективность» и установленного значения порога готовности платить за дополнительный QALY, однако он не позволяет учесть все аспекты ценности и требует использования затратной эффективности в качестве основного «драйвера» принятия решения о возмещении. Альтернативными подходами являются определение готовности платить за единицу агрегированной ценности (с учетом множества критериев) с помощью метода чистой денежной выгоды (net monetary benefit) или установление системы надбавок с учетом уровня ценности лекарствнного препарата. В настоящее время полноценно VBP на основе затратной эффективности используется только в Великобритании, в то время как в остальных странах используются его...

  • Open Access

    Overview of the existing opportunities and limitations of the state guarantees program for provision of free medical care to citizens

    by D. V. Fedyaev, R. V. Gostishchev, V. A. Lemeshko, O. I. Ivakhnenko

    Overview of the existing opportunities and limitations of the state guarantees program for provision of free medical care to citizens


  • Open Access

    International experience in determining the cost-effectiveness thresholds

    by T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky

    The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe (england and Wales, Scotland, Ireland, France, Belgium, Denmark, the netherlands, Germany, Sweden, Finland, norway, Poland), America (the USA, Canada, Brazil), Asia (Japan, South korea, Taiwan, Thailand), in Australia and new Zealand. The CeT is commonly used to rationalize decision-making in health cost reimbursement. The present review demonstrates that just a few countries (englandandWales,Thailand,Poland,USA) have introduced the explicit value of CeT into their decision making. Some countries (Australia,Canada,new Zealand, thenetherlands,Sweden, andBrazil) use CeT in an implicit manner implying that no specific CeT value is defined by law. In other countries (Finland,Sweden,norway,France,Germany,Denmark,Japan,South korea,Taiwan), the role of the threshold in health reimbursement remains uncertain despite the presence of HTA systems. The CeT is expressed as additional cost per unit of incremental health benefit, which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow using life years gained (LYG) as a measure of additional benefit neglecting the quality of life. In thenetherlandsandengland, different CeT values are applied to the health technology under assessment depending on the severity or rareness of the disease and some other factors.


  • Open Access

    Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions

    by G. R. Hachatryan, T. S. Teptsova, V. A. Lemeshko, N. Z. Musina

    The aimis to analyze the medical records of patients with malignant lymphoproliferative diseases (LPD) in the Russian Federation in 2016- 2017.Materials and methods. Treating physicians in 75 regions of the Russian Federation were asked to fill the survey questionnaire containing 9 types of malignant LPDs (according to the ICD-10 classification). The questions covered the epidemiology of LPD (prevalence, resistant forms, relapses and mortality), the existence of specialized institutions and beds, the costs of medical care in patients with malignant LPD, and the financial support of pharmacotherapy in these patients during their hospital stay.Results. We found that the most common malignant LPD in 2016-2017 was Hodgkin’s lymphoma (73.5 and 73.4%, respectively). The prevalence of resistant forms and recurrences of malignant LPD over this period accounted for 6.8% of the total patient population. In 2017, the number of patients who died was 7.5% less than that in 2016. There are 815 and 1,763 specialized institutions of the oncology and hematology profiles that provide medical care to children and adult patients, respectively. Among the malignant LPDs, the highest costs of drug therapy in 2016 pertained to lymphosarcoma, and in 2017 – to Hodgkin’s lymphoma. In the system of compulsory health insurance (OMC), the largest spending for both adult and pediatric patients in 2016 and 2017 was accounted for Hodgkin’s lymphoma; a similar result was obtained for the cost of therapy based on high-tech medical care.Conclusion. In 2017, the total number of patients with malignant LPD in the Russian Federation increased by 2.65% as compared to 2016, while the proportion of primary LPD decreased by 1.2%. In 2017, the total costs of drug supply in patients with malignant LPD in the RF increased by 55.35% as compared with 2016.